Double-Blind, randomized comparative study of the antihypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease

1991 ◽  
Vol 5 (3) ◽  
pp. 647-654 ◽  
Author(s):  
Friedrich-Karl Maetzel ◽  
Werner Eduard Teufel ◽  
Angela Griebel ◽  
Manfred Hagen Glocke
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Comparative Study ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Double Blind ◽  
Hypertensive Patients

scholarly journals DRUG INTERACTION BETWEEN CLOPIDOGREL AND RANITIDINE OR OMEPRAZOLE IN PATIENTS WITH CORONARY HEART DISEASE: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED COMPARATIVE STUDY

2014 ◽  
Vol 63 (12) ◽  
pp. A1521 ◽  
Author(s):  
Remo Holanda de Mendonca Furtado ◽  
Beatriz Tonon Freire ◽  
Celia Strunz ◽  
Carlos JDG Barbosa ◽  
André Franci ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Drug Interaction ◽  
Comparative Study ◽  
Double Blind

scholarly journals Efficacy and Safety of Zhenyuan Capsule for Coronary Heart Disease with Abnormal Glucose and Lipid Metabolism: Study Protocol for a Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Yu Qiao ◽  
Jingchun Zhang ◽  
Yue Liu ◽  
Zhiqi Liang ◽  
Yuhua Wang ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Lipid Metabolism ◽  
Blood Glucose ◽  
Glycosylated Hemoglobin ◽  
Postprandial Blood Glucose ◽  
Common Disease ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Glucose And Lipid Metabolism

Background. Coronary heart disease (CHD) and abnormal glucose and lipid metabolism are closely associated and generally coexist. The Qi and Yin deficiency syndrome is a common disease pattern encountered in traditional Chinese medicine. We designed a protocol to determine the effectiveness and safety of Zhenyuan capsules for CHD with abnormal glucose and lipid metabolism. Methods. This multicenter, randomized, double-blind, parallel-controlled trial was designed in accordance with the CONSORT. We will recruit 200 eligible male patients aged 45–75 years from three participating centers and randomly assign them to treatment and control groups (1 : 1). The primary indicators are glycosylated hemoglobin, fasting blood glucose, 2-hour postprandial blood glucose, and triglyceride levels. The secondary indicators are the Seattle Angina Questionnaire, TCM symptom indicators, ultrasonic cardiography finding, coagulation indicator, and P-selectin level. Measurements will be performed at baseline (T0), the end of the run-in period (T1), and weeks 4 (T2), 8 (T3), and 12 (T4) of the treatment period. Adverse events will be monitored during the trial. Discussion. This study aims to evaluate the efficacy and safety of Zhenyuan capsules in patients with CHD and abnormal glucose and lipid metabolism. The results will provide critical evidence of the usefulness of the Chinese herbal medicine for CHD with abnormal glucose and lipid metabolism. Trial Registration. This trial is registered with the Chinese Clinical Trials Registry, with identifier number ChiCTR-TRC-14004639, May 4, 2014.

scholarly journals Effect of a 36-month Pharmaceutical Care Program on the Coronary Heart Disease Risk in Elderly Diabetic and Hypertensive Patients

2011 ◽  
Vol 14 (2) ◽  
pp. 249 ◽  
Author(s):  
Paulo Roque Obreli Neto ◽  
Srecko Marusic ◽  
Divaldo Pereira De Lyra Júnior ◽  
Diogo Pilger ◽  
Joice Mara Cruciol-Souza ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Pharmaceutical Care ◽  
Coronary Heart Disease Risk ◽  
Disease Risk ◽  
Intervention Group ◽  
Care Program ◽  
Control Group ◽  
Hypertensive Patients ◽  
Heart Disease Risk

Purpose. To examine the effect of a pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. Methods. A total of 200 elderly (> 60 years) diabetic and/or hypertensive patients were recruited into a randomized, controlled, prospective clinical trial with a 36-month follow-up, developed in a public primary health care unit in a municipality in the Brazilian State of Sao Paulo. A range of clinical measurements were evaluated at the baseline and up to 36 months afterwards. The intervention group patients received pharmaceutical care from a clinical pharmacist, whereas the control group patients received their usual care from the medical and nursing staff. The Framingham scoring method was used to estimate changes in the 10-year coronary heart disease risk scores of all the patients. Results. A total of 194 patients completed the study. Significant reductions (p < 0.05) in the mean values (baseline vs. 36 months) for the systolic blood pressure [156.7mmHg vs 133.7mmHg; p

A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients

1988 ◽  
Vol 61 (7) ◽  
pp. D81-D85 ◽  
Author(s):  
Jean-Paul Fillastre ◽  
Brice Letac ◽  
Fernand Galinier ◽  
Gérard Le Bihan ◽  
Jean Schwartz
Keyword(s):  
Comparative Study ◽  
Double Blind ◽  
Hypertensive Patients

Effect of soluble-viscous dietary fibre on coronary heart disease risk score across 3 population health categories: data from randomized, double-blind, placebo-controlled trials

2020 ◽  
Vol 45 (7) ◽  
pp. 801-804
Author(s):  
Vladimir Vuksan ◽  
John L. Sievenpiper ◽  
Elena Jovanovski ◽  
Alexandra L. Jenkins ◽  
Allison Komishon ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Risk Score ◽  
Coronary Heart Disease Risk ◽  
Disease Risk ◽  
Blood Cholesterol ◽  
Double Blind ◽  
Framingham Risk ◽  
Heart Disease Risk

We applied the Framingham risk equation in healthy, metabolic syndrome, and diabetes populations, following treatment with viscous fibre from konjac-based blend (KBB). KBB yielded reduction in estimated risk score by 16% (1.04 ± 0.03 vs. 0.87 ± 0.04, p < 0.01) in type 2 diabetes, 24% (1.08 ± 0.01 vs. 0.82 ± 0.02, p < 0.01) in metabolic syndrome, and 25% (1.09 ± 0.05 vs. 0.82 ± 0.06, p < 0.01) in healthy individuals. Drivers for decreased risk were improvements in blood cholesterol and systolic blood pressure. The composite coronary heart disease risk across populations was reduced 22% (p < 0.01). Novelty Viscous fibre from konjac-xanthan reduced 10-year relative coronary heart disease using Framingham Risk Score across the glycemic status spectrum.

Sign in / Sign up

Export Citation Format

Share Document